Recent Biotech Financings: Xanodyne, Avid, Cephalon, And Proteon
This article was originally published in The Pink Sheet Daily
Executive Summary
Cash isn’t easy to come by, but financing is available for public and private biotechs, at the right price.
You may also be interested in...
For U.S. Biotechs, Money Is Available Again But It Doesn’t Come Cheap
Oncothyreon is typical of many small publicly traded biotechs these days: the Seattle-based biotech finished the first quarter of 2009 with just $15.4 million in cash and equivalents, necessitating a careful husbanding of finances. But because it's been enjoying a recent uptick in market cap, the oncology-focused biotech raised $11.1 million via a registered direct offering
For U.S. Biotechs, Money Is Available Again But It Doesn’t Come Cheap
Oncothyreon is typical of many small publicly traded biotechs these days: the Seattle-based biotech finished the first quarter of 2009 with just $15.4 million in cash and equivalents, necessitating a careful husbanding of finances. But because it's been enjoying a recent uptick in market cap, the oncology-focused biotech raised $11.1 million via a registered direct offering
Cephalon Purchases Majority Stake In Australian Biotech Arana, Clearing Way For Full-scale Acquisition
PERTH, Australia - Through ongoing buying of shares in the target company, Cephalon International Holdings has achieved a controlling 50 percent-plus interest in Australian biotech Arana. Cephalon's offer to acquire Arana is now "free from all outstanding conditions," Cephalon announced May 20